)  has signed a multi-product research agreement with 

) to explore the use of Emisphere’s eligen  technology in feasibility studies for new oral formulations of Roche molecules.  Research, funded by Roche, will be conducted at both companies’ sites.  Emisphere’s eligen technology is an oral drug delivery platform based on the  use of synthetic chemical compounds known as EMISPHERE delivery agents or  carriers. These molecules facilitate transportation of therapeutic macromolecules  across biological membranes to exert their desired pharmacological effect.

News

Emisphere Technologies, Inc. (Tarrytown, NY, www.emisphere.com) has signed a multi-product research agreement with Roche (Basel, Switzerland, www.roche.com) to explore the use of Emisphere's eligen technology in feasibility studies for new oral formulations of Roche molecules.